FDA Updates eMDR Electronic Medical Device Reporting System Enhancements Plan (June 26, 2026)

Source Information

Source organization: U.S. Food and Drug Administration (FDA)

Original date: June 26, 2026

Original link: https://www.fda.gov/medical-devices/emdr-electronic-medical-device-reporting/emdr-system-enhancements

This article is a professional English adaptation based on the FDA public page.

Full Translation of Core Content

The FDA has updated its eMDR (Electronic Medical Device Reporting) system enhancements plan. The update covers integration with AEMS, country code rules, maintenance of IMDRF adverse event codes, and the scheduling of test deployment for the electronic reporting system.

According to the FDA page, the eMDR system enhancements plan addresses AEMS integration, country code rules, IMDRF adverse event code maintenance, and test deployment arrangements for the electronic reporting system.

eMDR is a key infrastructure for the electronic reporting of medical device adverse events. System enhancements mean that, in their post-market reporting, companies need to verify whether data fields, code rules, submission formats, test environments and internal reporting processes are consistent with FDA system requirements.

For manufacturers and importers with products marketed in the United States, adverse event reporting is not simply a matter of completing a form. It is a combination of complaint identification, medical assessment, reportability determination, coding, timeline control and electronic submission capability.

AIMEILI Regulatory Interpretation

AIMEILI's Regulatory Affairs Department considers that updates of this kind reflect a global regulatory shift from "pre-market market access" toward "lifecycle-wide transparent management." UDI, EUDAMED, SSCP, adverse event terminology and electronic reporting systems appear to belong to different regulatory modules, but they all point to one requirement: after a product is placed on the market, it must be identifiable, traceable, updatable and publicly explainable, and the company must be able to demonstrate continued compliance through structured data.

For companies, this is not a question of a single label field or a database account. It is an integrated engineering task linking registration dossiers, packaging and labeling, ERP codes, distributor management, PMS plans, complaint handling, recall processes and certificate maintenance. If the model number on the registration certificate, the identifier on the label, the product information in the database, the terminology used in post-market reports and the actual sales scope of distributors are inconsistent, risks will arise in subsequent reviews, recalls or certificate renewals.

Business Impact

This update may affect a company's assessment of registration pathways, technical documentation preparation, labeling and instructions for use, quality management system records, or post-market maintenance arrangements. Companies should conduct an internal assessment based on the target market, product risk class, existing certificates and sales plans, rather than treating regulatory news as general information only.

AIMEILI recommends that companies establish a global product master data table as early as possible, covering at a minimum: product name, model and specification, intended use, risk class, certificate number, UDI/traceability code, label version, countries of sale, local responsible entity and post-market reporting requirements. In markets such as the European Union, Australia, the United States, Canada and Singapore, product data governance capability will increasingly affect a company's registration efficiency and its ability to maintain continuous market supply.

Recommended Compliance Actions

• Confirm whether the update affects existing registration pathways, certificate maintenance or post-market obligations.
• Verify technical documentation, labeling and instructions for use, quality management system arrangements and local responsible entity arrangements for target countries.
• Establish change impact assessments and regulatory update tracking records for marketed products.
• Where necessary, archive the official original text, translated interpretations and internal action items to support subsequent audits and project reviews.

Scope and Limitations

Content author: AIMEILI Regulatory Editorial Team

Professional review: AIMEILI Medical Device International Registration Project Team

Source principles: Priority is given to official regulatory authorities, international organizations, standards organizations and publicly available regulatory materials; industry media and project experience are used only as supporting reference.

Scope of application: This article is intended for preliminary understanding, documentation preparation and project planning. It does not replace the formal requirements of target-country regulatory authorities, testing conclusions or legal opinions.